{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-fluorouracil+%28+in+FOLFOX%29", "query": { "intervention": "5-fluorouracil ( in FOLFOX)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 159, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-fluorouracil+%28+in+FOLFOX%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T22:43:45.787Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00831181", "title": "Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "mesorectal excision", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Beth Israel Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2004-07", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2018-03-20", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00831181" }, { "nct_id": "NCT06820463", "title": "A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2025-04-24", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 17, "location_summary": "Duarte, California • Santa Monica, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06820463" }, { "nct_id": "NCT03250832", "title": "Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "TSR-033", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-08-08", "completion_date": "2023-02-13", "has_results": true, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 11, "location_summary": "Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250832" }, { "nct_id": "NCT01206530", "title": "FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer", "Colon Cancer", "Metastasis", "Adenocarcinoma" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-09", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01206530" }, { "nct_id": "NCT06598007", "title": "A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "CT3001", "type": "DRUG" }, { "name": "FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crossignal Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2024-09-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06598007" }, { "nct_id": "NCT04991948", "title": "Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unresectable Metastatic Colorectal Cancer" ], "interventions": [ { "name": "CYAD-101", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celyad Oncology SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-11-22", "completion_date": "2038-05-25", "has_results": false, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Tampa, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04991948" }, { "nct_id": "NCT01307956", "title": "Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Adenocarcinoma", "Stage IIA Esophageal Cancer", "Stage IIB Esophageal Cancer" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 11, "start_date": "2011-02-28", "completion_date": "2015-12-23", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307956" }, { "nct_id": "NCT00025142", "title": "Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025142" }, { "nct_id": "NCT02141295", "title": "A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Vanucizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2014-06-30", "completion_date": "2017-02-01", "has_results": true, "last_update_posted_date": "2020-03-25", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02141295" }, { "nct_id": "NCT00502567", "title": "A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "AZD2171", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Irinotecan (administered with & without Cetuximab)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2005-01", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-07-27", "last_synced_at": "2026-10-01T22:43:45.787Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan • Nashville, Tennessee", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00502567" } ] }